Selective effects of somatostatin analogs on human drug-metabolizing enzymes

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 2, 1998, Pages 150-159

  Rasmussen, Eva ^a   Eriksson, Barbro ^a   Öberg, Kjell ^a   Bondesson, Ulf ^a   Rane, Anders ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; CODEINE; GLIBENCLAMIDE; GLYCERYL TRINITRATE; IPRATROPIUM BROMIDE; METOPROLOL; NIFEDIPINE; OCTREOTIDE; OMEPRAZOLE; PANCREATIN; SOMATOSTATIN DERIVATIVE; TRYPTOPHAN;

ADULT; AGED; ARTICLE; CARCINOID SYNDROME; CLINICAL ARTICLE; DEMETHYLATION; DRUG EFFECT; DRUG METABOLISM; ENZYME METABOLISM; FEMALE; GLUCURONIDATION; GROWTH HORMONE RELEASE; GROWTH INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLIC CLEARANCE RATE; PRIORITY JOURNAL;

ADULT; AGED; ANALGESICS, OPIOID; CODEINE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HORMONE ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NEOPLASMS; SOMATOSTATIN;

EID: 0031665307     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90148-5     Document Type: Article

References (51)

1. Tannenbaum GS. Interrelationship of somatostatin and growth hormone-releasing hormone in the genesis of the rhythmic secretion of growth hormone. Acta Paediatr Scand 1990;367(suppl):76-80.
2. Gillies G. Somatostatin: the neuroendocrine story. Trends Pharmacol Sci 1997;18:87-94.
3. Shimatsu A, Murabe H, Sasaki S, Hattori N, Tanoh T, Imura H. Secretory dynamics of growth hormone in an acromegalic patient associated with Graves' disease. J Clin Endocr Metab 1990;71:1059-63.
4. Kuhn JM, Legrand A, Ruiz JM, Obach R, de Ronzan J, Thomas F. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue lanreotide, in normal healthy volunteers. Br J Clin Pharmacol 1994;38:213-9.
5. Hattori N, Shimatsu A, Sugita M, Kumagai S, Imura H. Immunoreactive growth hormone (GH) secretion by human lymphocytes: augmented release by exogenous GH. Biochem Biophys Res Commun 1990;168:396-401.
6. Blanck A, Hansson T, Näslund B, Rane A. Sex differences and endocrine regulation of morphine oxidation in rat liver. Biochem Pharmacol 1990;39:1820-2.
7. Blanck A, Hansson T, Assefaw-Redda Y, Rane A. Morphine-induced effects on hepatic metabolism in the male rat depend on an intact pituitary gland. Biochem Pharmacol 1990;40:2177-80.
8. Rane A, Ask B. A conspicuous down-regulation effect of morphine on essential steroid hydroxylation reactions and certain drug N-demethylations. J Steroid Biochem Mol Biol 1992;41:91-8.
9. Rane A, Bjelfman C, Thyr C, Porsch-Hällström I. Opiate-specific effects on mRNA and catalytic activity of a hepatic cytochrome P450 isozyme. Regul Pept 1994; (suppl 1):S273-8.
10. Redmond GP, Bell JJ, Perel JM. Effect of human growth hormone on amobarbital metabolism in children. Clin Pharmacol Ther 1978;24:213-8.
11. Redmond GP, Bell JJ, Nichola PS, Perel JM. Effect of growth hormone on human drug metabolism: time course and substrate specificity. Pedriatr Pharmacol 1978;1:63-70.
12. 2 breath test. Dev Pharmacol Ther 1989;12:90-5.
13. Cheung NW, Liddle C, Coverdale S, Lou JC, Boyages SC. Growth hormone treatment increases cytochrome P450-mediated antipyrine clearance in man. J Clin Endocrinol Metab 1996;81:1999-2001.
14. Watkins PB, Turgeon DK, Jaffe CA, Ho PJ, Barkan AL. Gender pulsation frequency of growth hormone may mediate gender differences in CYP3A activity in man [abstract]. Clin Res 1993;41:132A.
15. Kvols LK, Moertel CG, O'Connell MJ, Schutt AS, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. N Engl J Med 1986;315:663-6.
16. Öberg K. Endocrine tumours of the gastrointestinal tract: systemic treatment. Anticancer Drugs 1994;5:503-19.
17. Dayer P, Desmeules J, Striberni R. In vitro forecasting of drugs that may interfere with codeine bioactivation. Eur J Drug Metab Pharmacokinet 1992;17:115-20.
18. Ladona MG, Lindström B, Thyr C, Peng DR, Rane A. Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man. Br J Clin Pharmacol 1991;32:295-302.
19. Yue QY, Hasselström J, Svensson JO, Säwe J. Pharmacokinetics of codeine and its metabolites in caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. Br J Clin Pharmacol 1991;31:635-42.
20. Yue QY, Säwe J. Different effects of inhibitors on the O-and N-demethylation of codeine in human liver microsomes. Eur J Clin Pharmacol 1997;52:41-7.
21. Quiding H, Anderson P, Bondesson U, Boréus LO, Hynning PÅ. Plasma concentration of codeine and its metabolite, morphine, after single and repeated oral administration. Eur J Clin Pharmacol 1986;30:673-7.
22. Rane A, Modiri AR, Gerdin E. Ethylmorphine O-deethylation co-segregates with the debrisoquine genetic metabolic polymorphism. Clin Pharmacol Ther 1992;52:257-64.
23. Svensson JO. Determination of morphine, morphine-6-glucuronide and normorphine in plasma and urine with high-performance liquid chromatography and electrochemical detection. J Chromatogr 1986;375:174-8.
24. Wadelius M, Darj E, Frenne G, Rane A. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 1997;62:400-7.
25. Zaphiropoulos PG, Mode A, Norstedt G, Gustavsson JA. Regulation of sexual differentiation in drug and steroid metabolism. Trends Pharmacol Sci 1989;19:149-53.
26. Kobliakov V, Popova N, Rossi L. Regulation of the expression of the sex-specific isoforms of cytochrome P-450 in rat liver. Eur J Biochem 1991;195:585-91.
27. Kvistborg Fløgstad A, Halse J, Grass P, Abisch E, Djøseland O, Kutz K, et al. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J Clin Endocrinol Metab 1994;79:461-5.
28. Peyronneau MA, Delaforge M, Riviere R, Renaud JP, Mansuy D. High affinity of ergopeptides for cytochrome P450 3A: importance of their peptide moiety for P450 recognition and hydroxylation of bromocriptine. Eur J Biochem 1994;223:947-56.
29. Watkins PB, Murray SA, Winkleman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J Clin Invest 1989;83:688-97.
30. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-450PA (P450-1A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989;86:7696-700.
31. Ha HR, Che J, Freiburghaus AU, Follath F. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 1995;39:321-6.
32. Gu L, Gonzalez FJ, Kalow W, Tang BK. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992;2:73-7.
33. Buur Rasmussen B, Jeppesen U, Gaist D, Brøsen K. Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. Ther Drug Monit 1997;19:56-62.
34. Fuhr U, Doehmer J, Battula N, Wölfel C, Kudla C, Yango K, et al. Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem Pharmacol 1992;43:225-35.
35. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther 1996;59:613-23.
36. Sharer JE, Wrighton SA. Identification of the human cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos 1996;24:487-94.
37. Teunissen MW, De Leede LGJ, Boeijinga JK, Breimer DD. Correlation between antipyrine metabolite formation and theophylline metabolism in humans after simultaneous single-dose administration and at steady state. J Pharmacol Exp Ther 1985;233:770-5.
38. Ervine CM, Matthew DE, Brennan B, Houston JB. Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors: use of steady state infusion approach to achieve plasma concentrations-response relationships. Drug Metab Dispos 1996;24:211-5.
39. Rasmusson E, Ask B, Finnström N, Skottner-Lundin A, Rane A. IGF-I effects on sex-specific cytochrome P450 enzymes in normal and hypophysectomized male rats. Biochem Pharmacol [in press].
40. Barbare JC, Poupon R, Jaillon P, Bories P, Aussanaire M, Darnis F, et al. The influence of vasoactive agents on metabolic activity of the liver in cirrhosis: a study of the effects of posterior pituitary extract, vasopressin, and somatostatin. Hepatology 1984;4:59-62.
41. Lin HC, Tsai YT, Lee SD, Lee FY, Hsai HC, Meng HC, et al. Octreotide decreases liver metabolic activity in patients with hepatitis B surface antigen-positive cirrhosis. Clin Pharmacol Ther 1992;52:134-8.
42. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 2nd ed. Philadelphia: Lea & Febiger; 1989.
43. Kuhn JM, Basin C, Mollard M, de Rouge B, Baudoin C, Obach R, et al. Pharmacokinetic study and effects on growth hormone secretion in healthy volunteers of the new somatostatin analogue BIM 23014. Eur J Clin Pharmacol 1993;45:73-7.
44. Ottesen LH, Flyvbjerg A, Jakobsen P, Bendtsen F. The pharmacokinetics of octreotide in cirrhosis and in healthy man. J Hepatol 1997;26:1018-25.
45. del Pozo E, Neufeld M, Schlüter K, Tortosa F, Clarenbach P, Bieder E, et al. Endocrine profile of a long-acting somatostatin derivative SMS 201-995: study in normal volunteers following subcutaneous administration. Acta Endocrinol (Copenhagen) 1986;111:433-9.
46. Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut 1994;35(suppl3):S1-4.
47. Lightman SL, Fox P, Dunne MJ. The effect of SMS 201-995, a long-acting somatostatin analogue, on anterior pituitary function in healthy male volunteers. Scand J Gastroenterol 1986;21(suppl 119):84-95.
48. Gyr KE, Meier R. Pharmacodynamic effects of Sandostatin in the gastrointestinal tract. Digestion 1993;54 (suppl 1):14-9.
49. Persson K, Hammarlund-Udenaes M, Mortimer Ö, Rane A. The postoperative pharmacokinetics of codeine. Eur J Clin Pharmacol 1992;42:663-6.
50. Guay DRP, Awni WM, Findlay JWA, Halstenson CE, Abraham PA, Opsahl JA, et al. Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther 1988;43:63-71.
51. Sindrup SH, Brøsen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995;5:335-46.